Keros Therapeutics, Inc. (KROS) witnessed a significant surge of 6.89% in its stock price during Friday's intraday trading session. This rally was fueled by positive analyst coverage from prominent firms.
Scotiabank analyst Greg Harrison reiterated a Buy rating on Keros Therapeutics and set a price target of $44.00, reflecting the potential for substantial upside from the current levels. Additionally, Truist Financial analyst Srikripa Devarakonda also assigned a Buy rating to the stock, further boosting investor confidence.
The positive analyst sentiment appears to be a driving force behind the stock's impressive performance today. Investors are encouraged by the optimistic outlook from analysts, potentially signaling promising prospects for Keros Therapeutics in the near future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。